title: Management of Patients With Recovered Systolic Function.
abstract: Advancements in the treatment of heart failure (HF) with systolic dysfunction have given rise to a new population of patients with improved ejection fraction (EF). The management of this distinct population is not well described due to a lack of consensus on the definition of myocardial recovery, a scarcity of data on the natural history of these patients, and the absence of focused clinical trials. Moreover, an improvement in EF may have different prognostic and management implications depending on the underlying etiology of cardiomyopathy. This can be challenging for the clinician who is approached by a patient inquiring about a reduction of medical therapy after apparent EF recovery. This review explores management strategies for HF patients with recovered EF in a disease-specific format.
authors.affiliation: Ohio Health/Riverside Methodist Hospital, Columbus, OH. Electronic address: Anupam.Basuray@ohiohealth.com.
authors.forename: Anupam
authors.initials: A
authors.lastname: Basuray
authors.affiliation: University of Utah, Salt Lake City, UT. Electronic address: james.fang@hsc.utah.edu.
authors.forename: James C
authors.initials: JC
authors.lastname: Fang
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017147:Defibrillators, Implantable / Q000009:adverse effects; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D011379:Prognosis; D020127:Recovery of Function; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013318:Stroke Volume; D013599:Systole; D020257:Ventricular Remodeling
chemical_list: D000319:Adrenergic beta-Antagonists
keywords: Heart failure recovered ejection fraction; Myocardial recovery; Reverse remodeling